Beyond therapeutics, monoclonal antibodies shown to be effective in the clinic can help to facilitate laboratory research. Researchers use mAbs, also known as biosimilars, as tools to research novel therapies and uncover effective off-target applications. With known and approved data on toxicity and efficacy, researchers use these biologics as benchmarks in their studies, allowing them to accelerate their findings from bench to clinic.
ProSci offers more than 800 research-grade biosimilar antibodies in the following research areas: cancer, pain, blood-related diseases, bacterial infection, neurodegenerative, asthma, psoriasis and other dermatitis, rheumatoid arthritis and osteoporosis, inflammatory diseases, Crohn’s disease, virus infection, and diabetes and other autoimmune diseases.
Phone: 02 9698 2022
Biosensis MAP2 antibodies
Biosensis's validated MAP2 antibodies are designed to help users identify MAP2, whether they...
Bio-Rad Laboratories Celselect Slides validated antibodies for rare cell and CTC enumeration
The antibodies are specific to CTC surface markers to enable the sensitive and specific...
Microbiologics UV-BioTAG QC microorganisms for quality control testing
UV-BioTAG, a line of reference strains containing green fluorescent protein (GFP) markers, makes...
